Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | GRM5 | P41594 | 14/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3820812 | 0.82 | DHFR (0.54) | NPC1RAB9AGRM5KMT2AALDH1A1 | |
| SCHEMBL12680944 | 0.81 | GRM5 (0.60) | NPC1RAB9AGRM5GAA | |
| SCHEMBL15492431 | 0.80 | NPC1 (0.63) | NPC1RAB9AGRM5DPP4DPP8 | |
| SCHEMBL16286087 | 0.80 | DPP4 (0.52) | NPC1RAB9AGRM5DPP4DPP8 | |
| SCHEMBL13195580 | 0.79 | DPP4 (0.51) | NPC1RAB9AGRM5DPP4DPP8 | |
| SCHEMBL3540371 | 0.79 | ALDH1A1 (0.51) | NPC1RAB9AGRM5KMT2AKDM4E | |
| SCHEMBL30717323 | 0.77 | RAB9A (0.49) | NPC1RAB9AGRM5KMT2AKDM4E | |
| SCHEMBL15490041 | 0.77 | DPP8 (0.57) | NPC1RAB9AGRM5DPP4DPP8 | |
| SCHEMBL13494234 | 0.77 | DPP4 (0.49) | NPC1RAB9AGRM5DPP4DPP8 | |
| SCHEMBL13494214 | 0.77 | DPP4 (0.49) | NPC1RAB9AGRM5DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7645778-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093689-A1 | HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS | P2RY1, P2RY11, P2RY2 | NPC1 1830/4885RAB9A 1636/4885GRM5 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.